Dr. Clay B Siegall co-founded the company Seattle Genetics Inc. in the year 1997 and currently serves as the as the president and chairs the board of directors. He is also the Chief Executive Officer of the company. Siegall developed Seattle Genetics with the intention of performing thorough research, scientific innovations, and drug development exercises. Since the founding of the company, his leadership has seen its growth to a state where it has influence in other nations of the world. For instance, he has guided the company in the development of Antibody-drug conjugates (ADC) which is used in more than 60 states of the world. The success of the project was after teaming up with the Takeda Pharmaceutical Company.
Clay Siegall’s leadership has assisted in gaining Seattle Genetics excellent financial stability through their business operations and funding from private and public organizations as well as individuals including the initial public offering in 2001. He has also seen the company access several licenses for its technologies especially the ADC project. They include licenses with GlaxoSmithKline, Genentech, and Pfizer and have generated the company a significant amount of income. Currently, the clinical enhancements that use Clay’s ADCs from the collaborations accumulate to more than 20 in number.
The current emphasis that Clay Siegall has been putting is on research and development of the ADCs for the treatment of cancer. The research is motivated by the many years of experience he has had on the development of therapy drugs and research. Dr. Clay studied at George Washington University where he attained a Ph.D. in Genetics and thereafter enrolled with University of Maryland and attained his bachelor of science in zoology.
In addition to Seattle Genetics Inc., Clay Seigall serves on the board of directors for Ultragynex, Alder Biopharmaceuticals, and Mirna Therapeutics. He has also served at the National Cancer Institute and the National Institute of health before founding the Seattle Genetics. He is an award-winning icon including the entrepreneur of the year 2012 by the Pacific Northwest Ernst & Young. He has been writing publications and currently holds 15 patents.